MEK/ERK-dependent reactivation of Akt following long-term treatment led us to conclude that dual targeting of PI3K and MEK might be an effective approach to block NHEJ-dependent DSBs repair in NSCLC with a point mutation in the K-RAS gene. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.